Pyridones useful as inhibitors of kinases

A compound of formula I:

• or a pharmaceutically accepted salt thereof, wherein
• Q is C6-10aryl or 5-10 membered heteroaryl containing 1-4 heteroatoms selected from O, N, and S;
• Q is optionally substituted with 0-5 JQ;
• R is H or C1-6alkyl optionally substituted with C1-3alkyl, C1-2haloalkyl, halo, CN, NO2, OH, O(C1-4alkyl), NH2, NH(C1-4alkyl), N(C1-4alkyl)2 or C1-2haloalkyl;
• R2 is a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• wherein R2 is optionally substituted with 0-5 JR2;
• each R3 and R4 is independently H, halogen, or C1-4 aliphatic optionally substituted with 0-5 occurrences of halogen, OH, OCH3, OCF3, NO2, NH2, CN, NHCH3, SCH3, N(CH3)2, or C1-2aliphatic optionally substituted 0-5 times with F;
• each JQ and JR2 is independently halogen, |—NO2, —CN, U, —(U)m—(C6-10aryl), —(U)m-(5-12 membered heteroaryl), —(U)m-(3-12 membered heterocyclyl), —(U)m—(C3-10cycloaliphatic), —ORo, —SRo, —N(Ro)2, —(C1-6alkyl)-ORo, —(C1-6-alkyl)-N(Ro)2, —(C1-6alkyl)-SRo, —NRoC(O)Ro, —NRoC(S)Ro, —NRoC(O)N(Ro)2, —NRoC(S)N(Ro)2, —NRoCO2Ro, —NRoNRoC(O)Ro, —NRoNRoC(O)N(Ro)2, —NRoNRoCO2Ro, —C(O)C(O)Ro, —C(O)CH2C(O)Ro, —CO2Ro, —C(O)Ro, —C(S)Ro, —C(O)N(Ro)2, —C(S)N(Ro)2, —OC(O)N(Ro)2, —OC(O)Ro, —C(O)N(ORo)Ro, —C(NORo)Ro, —S(O)2Ro, —S(O)3Ro, —SO2N(Ro)2, —S(O)Ro, —NRoSO2N(Ro)2, —NRoSO2Ro, —N(ORo)Ro, —C(═NH)—N(Ro)2, —P(O)2Ro, —PO(Ro)2, —CPO(Ro)2, ═O, ═S, ═NNHRo, ═NN(Ro)2, ═NNHC(O)Ro, ═NNHCO2(C1-6alkyl), ═NNHSO2(C1-6alkyl), ═NOH, or ═NRo;
• wherein each JQ and JR2 is independently and optionally substituted with 0-5 RX;
• each RX is independently halogen, NO2, CN, NH2, NH(C1-4aliphatic), N(C1-4aliphatic)2, OH, O(C1-4aliphatic), O(C1-4haloaliphatic), CO(C1-4aliphatic), CO2H, CO2(C1-4aliphatic), C1-6aliphatic, C1-4haloaliphatic, phenyl, —O(Ph), 5-6 membered heteroaryl, C3-8cycloaliphatic, 5-8 membered heterocyclyl, —C1-6aliphatic-(Ph), —C1-6alkyl-(5-6 membered heteroaryl), —C1-6alkyl-(C3-8cycloaliphatic), —C1-6alkyl-(5-8 membered heterocyclyl), or C1-10alkylidene chain wherein up to 2 methylene units of the chain are optionally replaced by O, N, or S;
• wherein each RX and is independently and optionally substituted with 0-5 Jo;
• each Ro is independently H, C1-6aliphatic, C1-4haloaliphatic, CO(C1-4aliphatic), CO2(C1-4aliphatic), —SO2(C1-4aliphatic), SO2(Phenyl), phenyl, 5-6 membered heteroaryl, 5-8 membered heterocyclyl, C3-8cycloaliphatic, -C1-6aliphatic-(Ph), —C1-6alkyl-(5-6 membered heteroaryl), —C1-6alkyl-(5-8 membered heterocyclyl), —C1-6alkyl-(C3-8cycloaliphatic);
• or C1-10alkylidene chain wherein up to 2 methylene units of the chain are optionally replaced by O, N, or S;
• wherein said Ro is optionally substituted with 0-6 Jo;
• or two Ro, on the same substituent or different substituents, taken together with the atom(s) to which each Ro group is bound, form a 3-8 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• wherein said ring is optionally and independently substituted with 0-4 occurrences of halogen, NO2, CN, C1-4aliphatic, NH2, NH(C1-4aliphatic), N(C1-4aliphatic)2, OH, O(C1-4aliphatic), CO2H, CO2(C1-4aliphatic), O(haloC1-4 aliphatic), or haloC1-4aliphatic, wherein each of the Ro C1-4aliphatic groups is unsubstituted;
• each Jo is independently halogen, NO2, CN, C1-4 aliphatic, —NH2, —NH(C1-4 aliphatic), —N(C1-4 aliphatic)2, —OH, —O(C1-4aliphatic), —CO2H, —CO2(C1-4 aliphatic), —O(haloC1-4 aliphatic), and halo(C1-4 aliphatic), wherein each of the Jo C1-4aliphatic groups is unsubstituted.